The obsessive-compulsive disorder drugs market size is forecast to increase by $266.78M from 2021 to 2026, at a CAGR of 5.55%, according to a study by Technavio. The growth of the market will be driven by the rising prevalence of OCD, the launch of new molecules, and awareness programs for OCD.
The market's expansion is fueled by the abundance of SSRIs like fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, and escitalopram. Due to the high demand for SSRIs, numerous generic versions have been approved by significant nations and organizations, including the United States, the European Union (EU), and Japan. SSRIs with controlled release and sustained release are being developed by some businesses. During the forecast period, the market for these new drugs is expected to grow quickly.